Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Last updated: May 5, 2025
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Overall Status: Active - Recruiting

Phase

2

Condition

Sarcoma

Treatment

Intensity Modulated Radiation Therapy (IMRT)

MRI

Clinical Study ID

NCT05301283
MCC-21136
  • Ages > 18
  • All Genders

Study Summary

The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed and dated informed consent form

  • Stated willingness to comply with all study procedures and availability for theduration of the study

  • For women of childbearing potential: use of highly effective contraception for atleast 1 month prior to screening and agreement to use such a method during studyparticipation and for an additional 52 weeks after the end of radiation.

  • For males of reproductive potential: use of condoms or other methods to ensureeffective contraception with partner 52 weeks after radiation.

  • Agreement to adhere to Lifestyle Considerations (as outlined in protocol) throughoutstudy duration.

  • Pathologically (histologically or cytologically) proven diagnosis of high-grade (grade 2 or 3) Soft Tissue Sarcoma (STS) of the deep trunk and/or extremity.Clinical evidence should be documented, and may consist of pathology or imaging, andshould be sufficient to estimate the size of the primary (for T stage)

  • Primary site deemed resectable prior to the start of trial

  • American Joint Committee on Cancer (AJCC) 8th edition staging T1-4 N0 M0, noevidence of distant metastases

  • Patients must have clinically or radiographically evident measurable disease at theprimary site.

  • Pre-Radiation Therapy (RT) MRI within 4 weeks of the start of RT.

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 3.

  • Deemed a surgical candidate

  • Participant agrees to blood and plasma preservation for future analysis.

Exclusion

Exclusion Criteria:

  • Contraindications to an MRI

  • Positive urine pregnancy test

  • Gross total excision of primary STS, including an unplanned excision

  • Superficial sarcoma located primarily in the subcutaneous or cutaneous tissue

  • Prior radiation to the region of the study cancer that would result in overlap ofradiation therapy fields.

  • Participants with a medical condition or social situation that, at the discretion ofthe principal investigator, would preclude them from completion of the trial.

Study Design

Total Participants: 43
Treatment Group(s): 2
Primary Treatment: Intensity Modulated Radiation Therapy (IMRT)
Phase: 2
Study Start date:
May 18, 2022
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • Moffitt Cancer Center

    Tampa, Florida 33612
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.